Sandoz, Teva And Mylan Step Up On Hydroxychloroquine
As White House And FDA Ramp Up Coronavirus Research
To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.
You may also be interested in...
Mylan has waived US exclusivity rights to its generic version of AbbVie’s Kaletra, which is being investigated as a treatment for COVID-19, after a week of activity that has seen Israel move to compulsory-license generic versions of the brand and the originator step back from enforcing related intellectual property worldwide.
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.
Teva CEO Kåre Schultz has received full backing to add another year onto his five-year contract, with a significant rise in compensation available if Teva’s shareholders say so later this year.